{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:57:11Z","timestamp":1784869031823,"version":"3.55.0"},"reference-count":31,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>In patients with acromegaly on long-term treatment with long-acting somatostatin receptor ligands (SRLs), the time of blood collection for IGF-I measurement after injection is not well defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We aimed to assess serum IGF-I dynamics and variability in SRL-treated patients compared with surgically cured patients and healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty patients under SRLs considered controlled based on a normal previous IGF-I level, 10 patients cured by pituitary surgery, and 7 healthy subjects underwent 4 weekly IGF-I determinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In SRL-treated patients, the IGF-I SDS (mean\u2005\u00b1\u2005SD) was higher just before injection (0.34\u2005\u00b1\u20050.66) than at Day 7 (\u22120.33\u2005\u00b1\u20050.61; P\u2005=\u20050.0041) and Day 14 (\u22120.23\u2005\u00b1\u20050.60; P\u2005=\u20050.047) after injection, but it did not significantly vary in cured patients and healthy controls. The IGF-I CV was higher in SRL-treated patients than in cured patients or healthy controls (14.4\u2005\u00b1\u20057.6% vs 7.9\u2005\u00b1\u20054.4% and 8.3\u2005\u00b1\u20053.2%, respectively; P\u2005&amp;lt;\u20050.05 for both). Among SRL-treated patients, IGF-I CV was higher in \u201cnonoptimally controlled patients\u201d\u2014i.e., patients with at least one elevated IGF-I value out of 4 (n\u2005=\u20059) compared with \u201coptimally controlled\u201d patients for whom all 4 IGF-I SDS values were\u2005&amp;lt;\u20052.0 (21.3\u2005\u00b1\u20059.3 vs 11.6\u2005\u00b1\u20056.0%; P\u2005=\u20050.0019). The latter did not differ from surgically cured patients and healthy controls. The measurement at the farthest distance from the SRL injection was the most predictive of patients with nonoptimally controlled disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients treated with long-acting SRLs, IGF-I sampling at the farthest distance from SRL injection is the most informative and best predictor of optimal disease control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgac385","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T20:26:31Z","timestamp":1656620791000},"page":"e3644-e3653","source":"Crossref","is-referenced-by-count":24,"title":["IGF-I Variability Over Repeated Measures in Patients With Acromegaly Under Long-Acting Somatostatin Receptor Ligands"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8526-8046","authenticated-orcid":false,"given":"Luigi","family":"Maione","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, Service d\u2019Endocrinologie et des Maladies de la Reproduction , 94275 Le Kremlin-Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Albrici","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, Service d\u2019Endocrinologie et des Maladies de la Reproduction , 94275 Le Kremlin-Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Grunenwald","sequence":"additional","affiliation":[{"name":"Service d\u2019Endocrinologie et Maladies m\u00e9taboliques, P\u00f4le Cardio-Vasculaire et M\u00e9tabolique, CHU Larrey , 31059 Toulouse Cedex , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Mouly","sequence":"additional","affiliation":[{"name":"Service d\u2019Endocrinologie et Maladies m\u00e9taboliques, P\u00f4le Cardio-Vasculaire et M\u00e9tabolique, CHU Larrey , 31059 Toulouse Cedex , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Cimino","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, Service d\u2019Endocrinologie et des Maladies de la Reproduction , 94275 Le Kremlin-Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Lise","family":"Lecoq","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, Service d\u2019Endocrinologie et des Maladies de la Reproduction , 94275 Le Kremlin-Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Claude","family":"Souberbielle","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris H\u00f4pital Necker-Enfants Malades, D\u00e9partement de Physiologie , 75015 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Caron","sequence":"additional","affiliation":[{"name":"Service d\u2019Endocrinologie et Maladies m\u00e9taboliques, P\u00f4le Cardio-Vasculaire et M\u00e9tabolique, CHU Larrey , 31059 Toulouse Cedex , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5096-5722","authenticated-orcid":false,"given":"Philippe","family":"Chanson","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, Service d\u2019Endocrinologie et des Maladies de la Reproduction , 94275 Le Kremlin-Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"issue":"1","key":"2022081816100892200_CIT0001","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers."},{"issue":"1","key":"2022081816100892200_CIT0002","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev."},{"issue":"4","key":"2022081816100892200_CIT0003","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1210\/jc.2004-2009","article-title":"Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly","volume":"90","author":"Puder","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022081816100892200_CIT0004","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1210\/jc.2003-032041","article-title":"Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements","volume":"89","author":"Biermasz","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022081816100892200_CIT0005","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1210\/jc.2013-3757","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis","volume":"99","author":"Carmichael","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022081816100892200_CIT0006","first-page":"2779","article-title":"Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly","volume":"86","author":"Colao","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022081816100892200_CIT0007","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11102-017-0791-0","article-title":"Somatostatin receptor ligands in the treatment of acromegaly","volume":"20","author":"Gadelha","year":"2017","journal-title":"Pituitary."},{"issue":"11","key":"2022081816100892200_CIT0008","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2022081816100892200_CIT0009","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol."},{"issue":"9","key":"2022081816100892200_CIT0010","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1210\/jc.2016-1257","article-title":"Reference values for IGF-I serum concentrations: comparison of six immunoassays","volume":"101","author":"Chanson","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2022081816100892200_CIT0011","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1530\/EC-21-0175","article-title":"Reference values for IGF-I serum concentration in an adult population: use of the VARIETE cohort for two new immunoassays","volume":"10","author":"Sabbah","year":"2021","journal-title":"Endocr Connect."},{"issue":"2","key":"2022081816100892200_CIT0012","first-page":"190","article-title":"Least significant changes and monitoring time intervals for high-resolution pQCT-derived bone outcomes in postmenopausal women","volume":"15","author":"Kawalilak","year":"2015","journal-title":"J Musculoskelet Neuronal Interact."},{"key":"2022081816100892200_CIT0013","author":"Maione","year":"2022"},{"issue":"2","key":"2022081816100892200_CIT0014","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2265.2006.02450.x","article-title":"Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly","volume":"64","author":"Caron","year":"2006","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"1","key":"2022081816100892200_CIT0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1210\/jcem.82.1.3572","article-title":"Sandostatin LAR in acromegalic patients: long-term treatment","volume":"82","author":"Flogstad","year":"1997","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022081816100892200_CIT0016","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2265.2007.02878.x","article-title":"Long-term (up to 18 years) effects on GH\/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa","volume":"67","author":"Maiza","year":"2007","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"1","key":"2022081816100892200_CIT0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary."},{"issue":"4","key":"2022081816100892200_CIT0018","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: A consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord."},{"issue":"7","key":"2022081816100892200_CIT0019","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1210\/jc.2009-2670","article-title":"A consensus on criteria for cure of acromegaly","volume":"95","author":"Giustina","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022081816100892200_CIT0020","first-page":"1610","article-title":"Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion","volume":"76","author":"Blum","year":"1993","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022081816100892200_CIT0021","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1210\/jc.2003-032150","article-title":"Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development","volume":"89","author":"Milani","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2022081816100892200_CIT0022","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1210\/jc.2005-0901","article-title":"Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels","volume":"90","author":"Feelders","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2022081816100892200_CIT0023","first-page":"3267","article-title":"Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly","volume":"80","author":"Stewart","year":"1995","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022081816100892200_CIT0024","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1211\/0022357023123","article-title":"Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers","volume":"56","author":"Antonijoan","year":"2004","journal-title":"J Pharm Pharmacol."},{"issue":"5","key":"2022081816100892200_CIT0025","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1365-2265.2005.02372.x","article-title":"Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days","volume":"63","author":"Bronstein","year":"2005","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"7","key":"2022081816100892200_CIT0026","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1177\/0091270005277936","article-title":"Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles","volume":"45","author":"Astruc","year":"2005","journal-title":"J Clin Pharmacol."},{"key":"2022081816100892200_CIT0027","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-7525-2-13","article-title":"Acromegaly Quality of Life Questionnaire (AcroQoL)","volume":"2","author":"Badia","year":"2004","journal-title":"Health Qual Life Outcomes."},{"issue":"1","key":"2022081816100892200_CIT0028","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11102-015-0681-2","article-title":"SAGIT(R): clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot study","volume":"19","author":"Giustina","year":"2016","journal-title":"Pituitary."},{"issue":"6","key":"2022081816100892200_CIT0029","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s11102-017-0835-5","article-title":"Development of ACRODAT((R)), a new software medical device to assess disease activity in patients with acromegaly","volume":"20","author":"van der Lely","year":"2017","journal-title":"Pituitary."},{"issue":"12","key":"2022081816100892200_CIT0030","first-page":"3555","article-title":"International Multicenter Validation Study of the SAGIT(R) Instrument in Acromegaly","volume":"106","author":"Giustina","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022081816100892200_CIT0031","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11102-005-4241-z","article-title":"Serum IGF-1 in treated acromegaly - how normal is \u201cnormal\u201d?","volume":"8","author":"Lansang","year":"2005","journal-title":"Pituitary."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac385\/44648561\/dgac385.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/9\/e3644\/45476944\/dgac385.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/9\/e3644\/45476944\/dgac385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T12:22:05Z","timestamp":1660825325000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/9\/e3644\/6623843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,7,1]]},"published-print":{"date-parts":[[2022,8,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac385","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742215816.793594763","asserted-by":"object"}]},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,7,1]]}}}